Humacyte (HUMA) Net Margin (2020 - 2026)
Humacyte (HUMA) posted quarterly Net Margin of 6230.51% for Q1 2026, down 129085.0% year-over-year from N/an in Q1 2025, and up 5.9% quarter-over-quarter from 6620.99% in Q4 2025.
Humacyte (HUMA) Net Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Net Margin for 4 consecutive years, with 6230.51% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 129085.0% year-over-year to 6230.51%; the TTM figure through Mar 2026 stood at 8889.78% (up 1380616.0% YoY), while the FY2025 annual figure was 5731.11%, changed N/A from the prior year.
- Net Margin rose to 6230.51% in Q1 2026 per HUMA's latest filing, from 6620.99% in the prior quarter.
- Across five years, Net Margin topped out at 4939.65% in Q1 2025 and bottomed at 11423.24% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | -7,125.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,125.37% |
| Mar 31, 2026 | -6,230.51% |
| Dec 31, 2025 | -6,620.99% |
| Sep 30, 2025 | -11,423.24% |
| Jun 30, 2025 | -10,445.18% |
| Mar 31, 2025 | -4,939.65% |
| Sep 30, 2021 | -13,096.68% |
| Sep 30, 2020 | -1,943.11% |